•  
  •  
 

Corresponding Author

Ahmed Eldesouky Mohamed

Document Type

Original Article

Abstract

Background: Several investigations have demonstrated that Nasal and systemic corticosteroids may enhance the olfactory function of certain individuals, while others have found no significant effect.

Aim: To examine the effectiveness and safety of nasal and systemic corticosteroids in the therapy of chronic olfactory dysfunction following COVID-19.

Patient and methods: This randomized controlled clinical study was conducted on fifty non-hospitalized confirmed COVID-19 patients after recovery with persistent smell disorder. They were classified into two equal groups: Group A involved twenty-five cases who received 2 weeks of OC (methylprednisolone 0.5 mg/kg/day) and OT, and Group B involved twenty-five cases who received 2 weeks of NC (mometasone furoate spray 2 sprays inside every nostril once daily) and OT. This study was carried out in the Otorhinolaryngology Surgery Department at Al-Hussien University Hospital.

Results: In Group A, pre-treatment data related to smell disorders Normosmia, Hyposmia, Anosmia, and Cacosmia were (0%, 20%, 72%, and 8%), respectively, while post-treatment data were (0%, 8%, 20%, and 12%), respectively. In Group B, Pre-treatment data related to smell disorders Normosmia, hyposmia, anosmia, and cacosmia were 0%, 8%, 80%, and 12%, respectively, while post-treatment data were 56%, 20%, 24%, and 0%, respectively. Group A and Group B showed complete improvement, with percentages of 20% and 56%, respectively.

Conclusion: Nasal corticosteroids demonstrated further progress in the treatment of cases after COVID-19 infection than systemic corticosteroids. They may improve olfactory function in some cases. More investigation is required to confirm these findings.

Keywords

Nasal and Systemic Corticosteroids; Olfactory Dysfunction; COVID-19

Subject Area

ENT

Download

Share

COinS